Details of Disease

General Information of Disease (ID: DISYKID5)

• Disease Name: HER2/NEU overexpressing breast cancer
• Synonyms: HER2 Positive breast cancer; HER2 positive breast carcinoma; ERBB2 Overexpressing subtype of breast carcinoma; Her2-receptor positive breast cancer; HER2 Overexpressing breast carcinoma; HER2 Overexpressing subtype of breast carcinoma
• Disease Class: 2C60-2C6Y: Breast cancer
• Definition: A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER).
• Disease Hierarchy:
  DIS7DPX1: Breast cancer
  DISGN7ZY: Breast carcinoma by gene expression profile
  DISYKID5: HER2/NEU overexpressing breast cancer
• ICD Code: ICD-11: ICD-11: 2C60-2C65
• Disease Identifiers:
  MONDO ID: MONDO_0006244
  UMLS CUI: C1960398
  MedGen ID: 743175
  SNOMED CT ID: 427685000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NERATINIB MALEATE	DMEDU7B	Approved	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 29 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
E2F3	TTWIJYH	Limited	Altered Expression	[2]
EML4	TT92GY4	Limited	Biomarker	[3]
CA12	TTSYM0R	Disputed	Biomarker	[4]
FES	TTLBY21	Disputed	Biomarker	[5]
PTK6	TT6TH8V	Disputed	Biomarker	[6]
EPHA5	TTV9KOD	moderate	Altered Expression	[7]
CAPN2	TTG5QB7	Strong	Biomarker	[8]
CCNE2	TTLDRGX	Strong	Biomarker	[9]
CD274	TT8ZLTI	Strong	Altered Expression	[10]
CDK4	TT0PG8F	Strong	Biomarker	[11]
ERBB3	TTSINU2	Strong	Biomarker	[12]
ERBB4	TTWALCO	Strong	Biomarker	[13]
FANCF	TTNZKFJ	Strong	Biomarker	[14]
FASN	TT7AOUD	Strong	Altered Expression	[15]
HSD17B4	TTL1WGS	Strong	Posttranslational Modification	[16]
HSF1	TTN6STZ	Strong	Genetic Variation	[17]
HSP90AA1	TT78R5H	Strong	Biomarker	[18]
KDM5A	TTIG67W	Strong	Biomarker	[19]
LIN28A	TTO50LN	Strong	Altered Expression	[20]
P4HA1	TTNH25W	Strong	Altered Expression	[21]
PTK2B	TTTEFBV	Strong	Biomarker	[22]
SH3GL1	TTTYNAM	Strong	Biomarker	[23]
AOC1	TTM3B5R	Definitive	Biomarker	[24]
CDC37	TT5SOEU	Definitive	Biomarker	[25]
CLCN3	TT8XNZ7	Definitive	Altered Expression	[26]
CUL3	TTPCU0Q	Definitive	Biomarker	[27]
PAK2	TT279WO	Definitive	Biomarker	[28]
PKD2L1	TTAHD89	Definitive	Biomarker	[29]
YES1	TT0SQ8J	Definitive	Biomarker	[30]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NDUFS7	DEIW03B	Strong	Biomarker	[31]

This Disease Is Related to 44 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DOCK1	OTCFV3ON	Limited	Altered Expression	[32]
FGF5	OTQXGHBY	Limited	Altered Expression	[33]
GSDMB	OTWA7P10	Disputed	Altered Expression	[34]
NEURL1	OT2C4P70	Disputed	Biomarker	[35]
PPP1R1B	OTSIJMQ9	Disputed	Biomarker	[36]
PTPRO	OTFLKWOY	Disputed	Posttranslational Modification	[37]
TEAD4	OTJS0T2B	Disputed	Biomarker	[38]
ECD	OT3L3PCU	moderate	Biomarker	[39]
GPN3	OTZ4584O	moderate	Altered Expression	[40]
LYPLA1	OTENU47T	moderate	Biomarker	[41]
PCGF2	OTIY1J5L	moderate	Biomarker	[42]
PFKP	OTFP7AA8	moderate	Biomarker	[43]
ADGRF1	OTRAOBYH	Strong	Altered Expression	[44]
AK4	OTA0T02Q	Strong	Altered Expression	[45]
CDCP1	OTD7RRWK	Strong	Biomarker	[46]
ETV4	OT8C98UZ	Strong	Altered Expression	[47]
FABP7	OTRE2H4G	Strong	Biomarker	[48]
FOXF2	OTV20NGX	Strong	Altered Expression	[49]
HUNK	OTZR4GBH	Strong	Biomarker	[50]
IL2RG	OTRZ3OMY	Strong	Altered Expression	[51]
KIF2C	OTJ8G3NP	Strong	Biomarker	[52]
MAPK8IP2	OTDUHLN0	Strong	Biomarker	[53]
MPZL1	OTJSUUHR	Strong	Biomarker	[54]
MUC4	OTLT11V1	Strong	Biomarker	[7]
NMU	OTW9X7BQ	Strong	Altered Expression	[55]
NPAS2	OTMRT2TS	Strong	Biomarker	[56]
NRF1	OTOXWNV8	Strong	Biomarker	[2]
NUP43	OTDF5K8Y	Strong	Altered Expression	[57]
PLAAT3	OTVXXJ5K	Strong	Altered Expression	[58]
SCAMP1	OTFS4IKJ	Strong	Biomarker	[59]
SERTAD1	OTBHKZQP	Strong	Altered Expression	[60]
SLC25A43	OTY6MWVD	Strong	Genetic Variation	[61]
TADA3	OTNUAIO9	Strong	Biomarker	[62]
TFAP2C	OTUDIW05	Strong	Biomarker	[63]
ALDH1A3	OT1C9NKQ	Definitive	Altered Expression	[64]
BARD1	OTTC0Z9Y	Definitive	Genetic Variation	[65]
EFNA1	OTU2NUA2	Definitive	Biomarker	[66]
GRB7	OTF8Y9XY	Definitive	Biomarker	[67]
HOXC4	OT52VJ6V	Definitive	Biomarker	[38]
KCTD10	OT5HFZXU	Definitive	Biomarker	[27]
LMO4	OT5NDCT9	Definitive	Biomarker	[68]
RHOJ	OTWI65OA	Definitive	Biomarker	[69]
RMDN3	OTKO7AUM	Definitive	Altered Expression	[70]
SFMBT2	OTZQT61Q	Definitive	Altered Expression	[71]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.Breast Cancer Res Treat. 2018 Nov;172(2):469-485. doi: 10.1007/s10549-018-4905-9. Epub 2018 Aug 20.
• [3] Biomarkers for personalized oncology: recent advances and future challenges.Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30.
• [4] Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.Tumour Biol. 2016 Nov;37(11):14757-14764. doi: 10.1007/s13277-016-5351-0. Epub 2016 Sep 14.
• [5] Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.Cancer Chemother Pharmacol. 2016 Oct;78(4):685-95. doi: 10.1007/s00280-016-3107-6. Epub 2016 Aug 4.
• [6] Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.Cancer Biol Ther. 2013 Mar;14(3):237-45. doi: 10.4161/cbt.23295. Epub 2013 Jan 4.
• [7] EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.FASEB J. 2019 Apr;33(4):4851-4865. doi: 10.1096/fj.201701561RRRR. Epub 2019 Jan 8.
• [8] Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib.Oncotarget. 2018 Sep 7;9(70):33382-33395. doi: 10.18632/oncotarget.26078. eCollection 2018 Sep 7.
• [9] The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.Sci Rep. 2017 Jan 25;7:41309. doi: 10.1038/srep41309.
• [10] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.Sci Rep. 2019 Nov 13;9(1):16662. doi: 10.1038/s41598-019-52944-6.
• [11] Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Nave Metastatic Breast Cancer.Clin Cancer Res. 2020 Jan 1;26(1):110-121. doi: 10.1158/1078-0432.CCR-19-0751. Epub 2019 Sep 16.
• [12] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.Cancer Med. 2019 Mar;8(3):1258-1268. doi: 10.1002/cam4.1995. Epub 2019 Jan 31.
• [13] Neratinib in HER2-Positive Breast Cancer Patients.Ann Pharmacother. 2019 Jun;53(6):612-620. doi: 10.1177/1060028018824088. Epub 2019 Jan 4.
• [14] Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis.Front Pharmacol. 2018 Oct 17;9:1184. doi: 10.3389/fphar.2018.01184. eCollection 2018.
• [15] (-)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer.Molecules. 2018 May 11;23(5):1160. doi: 10.3390/molecules23051160.
• [16] Predictive value of genetic analysis for pathological complete response to preoperative treatment in HER2 positive, HR negative early breast cancer (PASSION trial).Jpn J Clin Oncol. 2018 Apr 1;48(4):388-391. doi: 10.1093/jjco/hyy024.
• [17] Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26.
• [18] The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2.
• [19] Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.Oncotarget. 2016 Jun 28;7(26):39931-39944. doi: 10.18632/oncotarget.9539.
• [20] Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.Breast Cancer Res Treat. 2016 Feb;156(1):135-47. doi: 10.1007/s10549-016-3744-9. Epub 2016 Mar 5.
• [21] Collagen prolyl 4-hydroxylase 1 is essential for HIF-1 stabilization and TNBC chemoresistance.Nat Commun. 2018 Oct 26;9(1):4456. doi: 10.1038/s41467-018-06893-9.
• [22] PYK2 promotes HER2-positive breast cancer invasion.J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0.
• [23] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.Breast Cancer Res. 2017 Oct 3;19(1):110. doi: 10.1186/s13058-017-0900-z.
• [24] ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.Expert Opin Biol Ther. 2018 Mar;18(3):335-341. doi: 10.1080/14712598.2018.1430761. Epub 2018 Jan 24.
• [25] DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.Cancer Lett. 2018 Oct 10;434:70-80. doi: 10.1016/j.canlet.2018.07.012. Epub 2018 Jul 11.
• [26] Transcriptional repression of human epidermal growth factor receptor 2 by ClC-3 Cl(-) /H(+) transporter inhibition in human breast cancer cells.Cancer Sci. 2018 Sep;109(9):2781-2791. doi: 10.1111/cas.13715. Epub 2018 Jul 28.
• [27] Cullin-3/KCTD10 E3 complex is essential for Rac1 activation through RhoB degradation in human epidermal growth factor receptor 2-positive breast cancer cells.Cancer Sci. 2019 Feb;110(2):650-661. doi: 10.1111/cas.13899. Epub 2019 Jan 8.
• [28] Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.Biochem Biophys Res Commun. 2018 Oct 20;505(1):187-193. doi: 10.1016/j.bbrc.2018.09.086. Epub 2018 Sep 20.
• [29] Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer.Biomaterials. 2019 Nov;222:119420. doi: 10.1016/j.biomaterials.2019.119420. Epub 2019 Aug 10.
• [30] Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017.
• [31] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27.
• [32] Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis.Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7434-9. doi: 10.1073/pnas.1213050110. Epub 2013 Apr 16.
• [33] Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.Clin Cancer Res. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. Epub 2019 Nov 7.
• [34] Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.
• [35] Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.Cancer Res. 2011 Feb 15;71(4):1454-64. doi: 10.1158/0008-5472.CAN-10-3093. Epub 2011 Feb 8.
• [36] t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.Oncotarget. 2015 Oct 20;6(32):33134-45. doi: 10.18632/oncotarget.5311.
• [37] PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.J Transl Med. 2013 Oct 3;11:245. doi: 10.1186/1479-5876-11-245.
• [38] Identification of key genes involved in HER2-positive breast cancer.Eur Rev Med Pharmacol Sci. 2016;20(4):664-72.
• [39] A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.Breast Cancer Res Treat. 2016 Nov;160(2):249-259. doi: 10.1007/s10549-016-4000-z. Epub 2016 Oct 5.
• [40] Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy Degree.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819870823. doi: 10.1177/1533033819870823.
• [41] Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.Clin Transl Oncol. 2017 Aug;19(8):976-988. doi: 10.1007/s12094-017-1629-y. Epub 2017 Feb 21.
• [42] Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.J Natl Cancer Inst. 2019 Jun 1;111(6):609-619. doi: 10.1093/jnci/djy151.
• [43] Whole genome DNA methylation signature of HER2-positive breast cancer.Epigenetics. 2014 Aug;9(8):1149-62. doi: 10.4161/epi.29632. Epub 2014 Jul 8.
• [44] GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24.
• [45] AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.Dis Markers. 2019 Nov 20;2019:8186091. doi: 10.1155/2019/8186091. eCollection 2019.
• [46] Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.Cell Rep. 2015 Apr 28;11(4):564-76. doi: 10.1016/j.celrep.2015.03.044. Epub 2015 Apr 16.
• [47] Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells.Oncol Res. 2012;20(5-6):187-95. doi: 10.3727/096504013x13589503482699.
• [48] FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis.Oncogene. 2019 Sep;38(37):6445-6460. doi: 10.1038/s41388-019-0893-4. Epub 2019 Jul 19.
• [49] The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.Cell Signal. 2016 Oct;28(10):1502-19. doi: 10.1016/j.cellsig.2016.06.021. Epub 2016 Jul 1.
• [50] Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.Oncotarget. 2018 Nov 13;9(89):35962-35973. doi: 10.18632/oncotarget.26311. eCollection 2018 Nov 13.
• [51] Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.PLoS One. 2012;7(6):e39626. doi: 10.1371/journal.pone.0039626. Epub 2012 Jun 21.
• [52] A multi-layer inference approach to reconstruct condition-specific genes and their regulation.Bioinformatics. 2013 Jun 15;29(12):1541-52. doi: 10.1093/bioinformatics/btt186. Epub 2013 Apr 22.
• [53] Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).Ther Adv Med Oncol. 2018 Nov 9;10:1758835918807339. doi: 10.1177/1758835918807339. eCollection 2018.
• [54] MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells.Sci Rep. 2017 Sep 14;7(1):11514. doi: 10.1038/s41598-017-11876-9.
• [55] Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.Int J Cancer. 2017 Jun 15;140(12):2771-2784. doi: 10.1002/ijc.30705.
• [56] Loss of circadian clock gene expression is associated with tumor progression in breast cancer.Cell Cycle. 2014;13(20):3282-91. doi: 10.4161/15384101.2014.954454.
• [57] High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer.Future Oncol. 2018 Jun;14(15):1431-1442. doi: 10.2217/fon-2017-0690. Epub 2018 Feb 6.
• [58] High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer.J Thorac Dis. 2017 Apr;9(4):1002-1011. doi: 10.21037/jtd.2017.03.108.
• [59] MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.Cell Death Dis. 2018 Mar 1;9(3):344. doi: 10.1038/s41419-018-0364-9.
• [60] Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis.Cancers (Basel). 2019 Mar 8;11(3):337. doi: 10.3390/cancers11030337.
• [61] The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines.Oncol Rep. 2013 Apr;29(4):1268-74. doi: 10.3892/or.2013.2247. Epub 2013 Jan 23.
• [62] Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.Cell Cycle. 2017 Aug 18;16(16):1515-1525. doi: 10.1080/15384101.2017.1339846. Epub 2017 Jul 31.
• [63] EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Mol Cancer Ther. 2016 Mar;15(3):503-11. doi: 10.1158/1535-7163.MCT-15-0548-T. Epub 2016 Feb 1.
• [64] Identification of new cancer stem cell markers and signaling pathways in HER?positive breast cancer by transcriptome sequencing.Int J Oncol. 2019 Nov;55(5):1003-1018. doi: 10.3892/ijo.2019.4876. Epub 2019 Sep 12.
• [65] Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018.
• [66] The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.Cancer Res. 2016 Apr 1;76(7):1825-36. doi: 10.1158/0008-5472.CAN-15-0847. Epub 2016 Feb 1.
• [67] Epigenetically altered miR?93a?p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.Int J Mol Med. 2019 Jun;43(6):2352-2360. doi: 10.3892/ijmm.2019.4167. Epub 2019 Apr 15.
• [68] LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.Am J Cancer Res. 2018 Apr 1;8(4):594-609. eCollection 2018.
• [69] Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.
• [70] Crosstalks of the PTPIP51 interactome revealed in Her2 amplified breast cancer cells by the novel small molecule LDC3/Dynarrestin.PLoS One. 2019 May 10;14(5):e0216642. doi: 10.1371/journal.pone.0216642. eCollection 2019.
• [71] Biological function of long noncoding RNA snaR in HER2-positive breast cancer cells.Tumour Biol. 2017 Jun;39(6):1010428317707374. doi: 10.1177/1010428317707374.